Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Business Sale Proceeds

Business Sale Proceeds at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's business sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's business sale proceeds?
Jazz Pharmaceuticals (JAZZ) reported business sale proceeds of $200M in Q1 2026.
What does business sale proceeds mean?
Cash received from selling parts of the business.
How do you interpret business sale proceeds?
Higher proceeds indicate successful divestment of non-core assets, potentially providing liquidity for other strategic initiatives.
How does business sale proceeds compare across companies?
Occurs sporadically during corporate restructuring or portfolio optimization.